GlassScriptPhysician profile
Shannon Lacovic
NPI 1780121145
$3,519.12
in general payments reported to CMS, 2019-2025
36 companies · $811 in 2025
The $811 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $560 · 2022: $903 · 2023: $761 · 2024: $485 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.63 | 2021-2025 | |
| Novo Nordisk INC | $260.12 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $239.49 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $213.22 | 2021-2025 | Farxiga, Breztri |
| Amgen INC. | $165.76 | 2021-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.90 | 2022-2025 | Xifaxan |
| Revance Therapeutics, INC. | $155.79 | 2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.97 | 2021-2023 | Synjardy, Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $132.75 | 2021-2023 | |
| Exact Sciences Corporation | $126.75 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $126.01 | 2025 | Rexulti |
| Pfizer INC. | $98.97 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $94.94 | 2021 | |
| Axsome Therapeutics, INC. | $94.70 | 2023-2025 | Auvelity, Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $75.29 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $69.07 | 2024 | |
| Mylan Specialty L.P. | $62.91 | 2022-2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $62.32 | 2021 | |
| Merck Sharp & Dohme LLC | $50.49 | 2021-2024 | Vaxelis, Gardasil, Vaxneuvance |
| Vanda Pharmaceuticals INC. | $48.70 | 2021 | |
| Merz North America, INC. | $48.25 | 2025 | |
| Glaxosmithkline, LLC. | $43.30 | 2021-2024 | Shingrix, Boostrix, Arexvy |
| Janssen Pharmaceuticals, INC | $28.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.70 | 2021-2022 | |
| Abbott Laboratories | $27.28 | 2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $19.73 | 2025 | Veozah |
| Ascensia Diabetes Care US INC. | $17.73 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.42 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $16.16 | 2022 | |
| Corium, LLC | $15.59 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.34 | 2023 | |
| Seqirus USA INC | $15.32 | 2024 | Fluad, Flucelvax |
| Pulmonx Corporation | $15.14 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Genentech USA, INC. | $14.90 | 2021 | |
| Halozyme INC | $14.69 | 2023 | |
| Phathom Pharmaceuticals, INC. | $11.48 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Lacovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.